deltatrials
Completed PHASE1 NCT00000739

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Sponsor: Jacobus Pharmaceutical

Conditions HIV Infections Pneumonia, Pneumocystis Carinii
Interventions Dapsone
Updated 7 times since 2017 Last updated: Oct 27, 2021 Completion: Jun 30, 1998

A PHASE1 clinical study on HIV Infections and Pneumonia, Pneumocystis Carinii, this trial is completed. The trial is conducted by Jacobus Pharmaceutical and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jacobus Pharmaceutical
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Aurora, United States, Bayamón, Puerto Rico, Boston, United States, Brooklyn, United States, Charleston, United States, Chicago, United States, Cleveland, United States, Detroit, United States, Durham, United States and 24 more location s